22 related articles for article (PubMed ID: 38591902)
1. Soy consumption and histopathologic markers in breast tissue using tissue microarrays.
Maskarinec G; Erber E; Verheus M; Hernandez BY; Killeen J; Cashin S; Cline JM
Nutr Cancer; 2009; 61(5):708-16. PubMed ID: 19838945
[TBL] [Abstract][Full Text] [Related]
2. The impact of modified staining method on HER2 immunohistochemical staining for HER2-low breast cancer.
Chen YY; Yang CF; Hsu CY
Pathology; 2024 Feb; 56(1):122-124. PubMed ID: 37657990
[No Abstract] [Full Text] [Related]
3. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
[TBL] [Abstract][Full Text] [Related]
4. Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
Calhoun BC; Mosteller B; Warren D; Smith M; Jordi Rowe J; Lanigan CP; Mrazeck KC; Walker E; Newell AH; Jones R
Ann Diagn Pathol; 2018 Aug; 35():21-26. PubMed ID: 29758480
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
[TBL] [Abstract][Full Text] [Related]
6. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
[TBL] [Abstract][Full Text] [Related]
7. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates.
Rakha EA; Chmielik E; Schmitt FC; Tan PH; Quinn CM; Gallagy G
Pathobiology; 2022; 89(5):263-277. PubMed ID: 35728576
[TBL] [Abstract][Full Text] [Related]
9. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.
Jorns JM
Arch Pathol Lab Med; 2019 Dec; 143(12):1444-1449. PubMed ID: 31373514
[TBL] [Abstract][Full Text] [Related]
11. [Comparative immunohistochemistry study of different antibodies clones for detection of breast cancer markers (estrogen receptor, progesterone receptor, HER2/neu, Ki-67)].
Kalinin DV; Samoylova DV; Danilova NV; Germanovich NY; Kuznetsova OA; Zavalishina LE
Arkh Patol; 2024; 86(2):14-20. PubMed ID: 38591902
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]